

Retatrutide - related reports

Privacy-redacted supplier copies

Read this notice with every report

These supplier-provided reports were commissioned by third parties, not Encore. Customer-identifying fields and lookup credentials were redacted by Encore for privacy. This cover is Encore-authored; the reports are not laboratory reissues or new Encore certificates.

Authenticity and inventory correspondence: Not verified

The owner confirms supplier permission for public sharing and reports supplier confirmation of received lots. Neither report authenticity nor correspondence to current Encore inventory has been independently established. Findings apply only to the tested samples and stated scope; no result is attributed to current stock.

Scope and outstanding questions

Selected reports name 10 mg and 20 mg samples. The MZ 10 mg report covers identity/purity, not net content. A separate 30 mg report states 36 mg / 120%, outside its printed 90-110% range; it remains unresolved and is not included here. Other quantity differences remain unresolved. No 25 mg report was located.

Privacy and verification limits

Laboratory identity, sample/report references, dates, results, graphs and limitations remain. Retained references and copies elsewhere may still identify the original customer. Redaction does not guarantee anonymity, and removed lookup credentials limit direct public verification.

Included reports

Janoshik | Retatrutide 10 mg | pages 2-2

MZ Biolabs | Retatrutide 10 mg | pages 3-4

BTLabs | Retatrutide 20 mg | pages 5-6

TEST REPORT

JANOSHIK

E-mail: info@janoshik.com
Web: www.janoshik.com

Task Number #101082

Testing ordered > 08 JAN '26

Sample received > 16 JAN '26

Client

REDACTED

SampleRetatrutide 10mg | Ships within the U.S.A. - Fast

Manufacturer

REDACTED

BatchRT10/2026-01-09-A

Sample description >

See picture or pictures attached.

Tests requested >

Assessment of a peptide vial or vials.

Results >

QR
REMOVED

Retatrutide	10.36 mg; 10.06 mg.
Purity	99.627%; 99.691%.

Comments >

Analysis conducted > 22 JAN 2026

Signature > 

Verify this test at www.janoshik.com/verify/ with the following unique key

KEY REMOVED

Certificate of Analysis

Retatrutide 10mg


Compound : Retatrutide
Lot number : 2026-07-01
Analysis date : 2026-07-10
Purity % : 99.23%
Method : HPLC-UV-MS

Client : REDACTED

PubChem CID : 171934787

<https://pubchem.ncbi.nlm.nih.gov/compound/171934787>

High Performance Liquid Chromatography (HPLC) UV – Purity Test



PEAK LIST		Number of detected peaks: 4		
	Time (min)	Area	%Area	
1	6.57	2.70E+01	0.05	
2	6.72	5.18E+04	99.23	Retatrutide
3	6.99	6.83E+01	0.13	
4	7.22	3.05E+02	0.58	

Analysis Performed by
Ken Pendarvis, ChE
Analytical Chemist
MZ Biolabs
contact@mzbiolabs.com



2026-07-17

Note: Injectable peptides may contain salts and sugars to aid in solubility and act as pH buffers.
These are not normally detected using UV and are not considered impurities.

Retatrutide 10mg

PubChem CID : 171934787

<https://pubchem.ncbi.nlm.nih.gov/compound/171934787>

Mass Spectrometry (MS) – Identity Test

Identity confirmed using HPLC-MS

Molecular weight calculated using monoisotopic m/z values from mass spectrum

Expected monoisotopic mass : 4728.47 Da


Measured monoisotopic mass : 4728.47 Da

Molecular weight confirmed

Note : Monoisotopic m/z values are not easily seen in full spectrum view for larger molecules and peptides.

The dominant isotopic peak (base peak) shown in the spectrum below can be used to approximate the average molecular weight frequently reported by vendors and databases as a secondary means of confirmation.

Recorded MS spectrum



Analysis Performed by
Ken Pendarvis, ChE
Analytical Chemist
MZ Biolabs
contact@mzbiolabs.com



2026-07-17




Report #: COA261404-001

Page 1 of 2

Title:

Certificate of Analysis (CoA)



Date: 9/15/2026
Date Tested: 9/12/2026
Customer: REDACTED
Testing material: Retatrutide
Lot Number: V7-802601-RETA
Sample ID: BTL260828-006-001
Content/Potency: 20 mg
Storage: R.T.
Visual Description: Small clear vial: white sample, white label, silver crimp, clear pink plastic cap.
Labeled as: Retatrutide
Manufacturer: N/A
Testing Purpose: FTIR and HPLC analysis for the identification, purity, potency and composition of a peptide product. It does not provide information on particulate matter, microbial contamination or presence of endotoxins.



Test	Method	Specification	Result
General Appearance	USP <630>	white powder	white powder
Mass	USP <41>	As recorded	114.6 mg
FTIR Identification and Composition Analysis	USP <197A>	Sample spectrum should confirm the content of peptide via characteristic bands	FTIR sample spectrum confirms the presence of Retatrutide with addition of excipient(s)/fillers.
HPLC Purity of Peptide Assay	USP <621>	Specifications: ≥ 98 %	99.7 %
HPLC Potency Assay	USP <621>	Specifications: 90 – 110% of 20 mg	21.8 mg (109.1 %)
Peptide-to-Excipients Ratio	USP <1151>	Recommended ratios of (1:0) to (1:10) for (peptide: excipients)	21.8 : 92.8 mg (1:4.3)

The results of the CoA relate only to the item(s) tested and applied to the sample as received.

Andrea Castro, BS
 Scientist-II
 BTLabs

Escarlet Cabrieles, BS
 Scientist-II
 BTLabs

5601 Corporate Way | Suite 206 | West Palm Beach, FL 33407
 Phone: (561) 625-0133
 E-mail: info@btlabtesting.com | Website: https://btlabtesting.com

IF-824-QSA-TR006
 Rev 1.1 August 2026




Report #:

COA261404-001


Page 2 of 2

Title:


Certificate of Analysis (CoA)



FTIR ID and Composition Analysis: Retatrutide Lot V7-802601-RETA



HPLC Purity and Potency Assay @ 280 nm: Retatrutide Lot V7-802601-RETA



5601 Corporate Way | Suite 206 | West Palm Beach, FL 33407
 Phone: (561) 625-0133
 E-mail: info@btlabtesting.com | Website: <https://btlabtesting.com>

IF-824-QSA-TR006
 Rev 1.1 August 2026